The United States Patent and Trademark Office (USPTO) has issued patent US12584174B2 to Regeneron Pharmaceuticals, Inc. This patent, titled "Treatment of psoriasis with interferon induced Helicase C domain 1 (IFIH1) inhibitors," was granted on March 24, 2026, based on an application filed on June 9, 2022. The patent covers methods for treating subjects with psoriasis and identifying those at increased risk of developing the condition, specifically through the use of IFIH1 inhibitors.

This is a grant of intellectual property and does not impose new regulatory obligations on other entities. However, it signifies Regeneron's exclusive rights to the patented treatment methods. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in psoriasis research or treatment, should be aware of this patent to avoid potential infringement. No immediate compliance actions are required for other entities, but it may influence future research and development strategies.